Literature DB >> 27336057

Evidence of structural invariance across three groups of Meehlian schizotypes.

Raymond Ck Chan1, Diane C Gooding2, Hai-Song Shi3, Fu-Lei Geng3, Dong-Jie Xie3, Zhuo-Ya Yang3, Wen-Hua Liu4, Yi Wang1, Chao Yan5, Chuan Shi6, Simon Sy Lui7, Eric Fc Cheung8.   

Abstract

According to Meehl's model of schizotypy, there is a latent personality organization associated with the diathesis for schizophrenia that can be identified in several ways. We sought to examine the structural invariance of four Chapman psychosis-proneness scales (CPPS) across three groups of putative schizotypes, namely, clinically-, biologically-, and psychometrically-identified schizotypes. We examined the factor structure of the Perceptual Aberration (PER), Magical Ideation (MIS), Revised Social Anhedonia (RSAS), and Revised Physical Anhedonia (RPAS) scales in 196 schizophrenia patients, 197 non-psychotic first-degree relatives, and 1,724 non-clinical young adults. The confirmatory factor analyses indicated that the best-fitting model was one in which there is a two-factor model with negative schizotypy (RSAS and RPAS) and positive schizotypy (PER and MIS). All three samples fit the model well, with Comparative Fit Indices>0.95 and Tucker Lewis Indices>0.90. The root mean square error of approximations were all small (P values⩽0.01). We also observed that for both anhedonia scales, the groups' mean scale scores varied in the hypothesized direction, as predicted by Meehl's model of schizotypy. All three Chinese samples, namely, the patients (clinical schizotypes), relatives (biologically-identified schizotypes), and non-clinical young adults (containing psychometrically-identified schizotypes) showed the same factorial structure. This finding supports the suitability of the CPPS for cross-cultural and/or genetic investigations of schizotypy.

Entities:  

Year:  2016        PMID: 27336057      PMCID: PMC4900100          DOI: 10.1038/npjschz.2016.16

Source DB:  PubMed          Journal:  NPJ Schizophr        ISSN: 2334-265X


  26 in total

1.  A cross-validation study of clustering of schizotypy using a non-clinical Chinese sample.

Authors:  Yi Wang; David Neumann; David Ho-keung Shum; Raymond Chor-kiu Chan
Journal:  Psychiatry Res       Date:  2012-04-24       Impact factor: 3.222

Review 2.  Mode of questionnaire administration can have serious effects on data quality.

Authors:  Ann Bowling
Journal:  J Public Health (Oxf)       Date:  2005-05-03       Impact factor: 2.341

3.  Power and sensitivity of alternative fit indices in tests of measurement invariance.

Authors:  Adam W Meade; Emily C Johnson; Phillip W Braddy
Journal:  J Appl Psychol       Date:  2008-05

4.  Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia.

Authors:  K S Kendler; L Thacker; D Walsh
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

5.  The Chapman psychosis-proneness scales: Consistency across culture and time.

Authors:  Raymond C K Chan; Hai-song Shi; Fu-lei Geng; Wen-hua Liu; Chao Yan; Yi Wang; Diane C Gooding
Journal:  Psychiatry Res       Date:  2015-04-30       Impact factor: 3.222

6.  Thought disorder in mid-childhood as a predictor of adulthood diagnostic outcome: findings from the New York High-Risk Project.

Authors:  D C Gooding; S L Ott; S A Roberts; L Erlenmeyer-Kimling
Journal:  Psychol Med       Date:  2012-08-30       Impact factor: 7.723

7.  Body-image aberration in Schizophrenia.

Authors:  L J Chapman; J P Chapman; M L Raulin
Journal:  J Abnorm Psychol       Date:  1978-08

8.  Anhedonia and perceptual aberration in first-episode psychotic patients and their relatives.

Authors:  J Katsanis; W G Iacono; M Beiser
Journal:  J Abnorm Psychol       Date:  1990-05

Review 9.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

10.  The Genetic Basis of Thought Disorder and Language and Communication Disturbances in Schizophrenia.

Authors:  Deborah L Levy; Michael J Coleman; Heejong Sung; Fei Ji; Steven Matthysse; Nancy R Mendell; Debra Titone
Journal:  J Neurolinguistics       Date:  2010-05-01       Impact factor: 1.710

View more
  4 in total

1.  Inheritance of Neural Substrates for Motivation and Pleasure.

Authors:  Zhi Li; Yi Wang; Chao Yan; Eric F C Cheung; Anna R Docherty; Pak C Sham; Raquel E Gur; Ruben C Gur; Raymond C K Chan
Journal:  Psychol Sci       Date:  2019-07-18

2.  Enhancing Psychosis-Spectrum Nosology Through an International Data Sharing Initiative.

Authors:  Anna R Docherty; Eduardo Fonseca-Pedrero; Martin Debbané; Raymond C K Chan; Richard J Linscott; Katherine G Jonas; David C Cicero; Melissa J Green; Leonard J Simms; Oliver Mason; David Watson; Ulrich Ettinger; Monika Waszczuk; Alexander Rapp; Phillip Grant; Roman Kotov; Colin G DeYoung; Camilo J Ruggero; Nicolas R Eaton; Robert F Krueger; Christopher Patrick; Christopher Hopwood; F Anthony O'Neill; David H Zald; Christopher C Conway; Daniel E Adkins; Irwin D Waldman; Jim van Os; Patrick F Sullivan; John S Anderson; Andrey A Shabalin; Scott R Sponheim; Stephan F Taylor; Rachel G Grazioplene; Silviu A Bacanu; Tim B Bigdeli; Corinna Haenschel; Dolores Malaspina; Diane C Gooding; Kristin Nicodemus; Frauke Schultze-Lutter; Neus Barrantes-Vidal; Christine Mohr; William T Carpenter; Alex S Cohen
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

3.  Clustering of Schizotypal Features in Unaffected First-Degree Relatives of Schizophrenia Patients.

Authors:  Simon S Y Lui; Karen S Y Hung; Yi Wang; Karen K Y Ho; Hera K H Yeung; Ya Wang; Jia Huang; Diane C Gooding; Eric F C Cheung; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

4.  A novel construct of anhedonia revealed in a Chinese sample via the Revised Physical and Social Anhedonia Scales.

Authors:  Qiongqiong Wu; Jiayue He; Shulin Fang; Panwen Zhang; Xingwei Luo; Jianghua Zhang; Yan Xiong; Fusheng Luo; Xiaosheng Wang; Shuqiao Yao; Xiang Wang
Journal:  BMC Psychiatry       Date:  2020-11-09       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.